Targets › ARNT
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2027.
Transcription factor that functions as an obligate heterodimerization partner for several basic helix-loop-helix PER-ARNT-SIM (bHLH-PAS) proteins. Forms heterodimers with the aryl hydrocarbon receptor (AHR) to mediate the transcriptional response to xenobiotics by binding xenobiotic response elements (XREs) or dioxin response elements (DREs) in target gene promoters. (UniProt, P27540)
Open in Phaseline: the race on ARNT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Neomorph | NEO-811 ARNT molecular glue degrader | ARNT | Phase 1 | Clear Cell Renal Cell Carcinoma | Jan 2027 |
Clear Cell Renal Cell Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.